[HTML][HTML] Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis
K Heffernan, FS Nikitas, U Shukla, HS Camejo… - Gynecologic …, 2022 - Elsevier
Objectives In patients with recurrent/advanced endometrial cancer who have progressed
after first-line treatment, there are a lack of real-world data on treatment patterns …
after first-line treatment, there are a lack of real-world data on treatment patterns …
Characterization of GEXP15 as a Potential Regulator of Protein Phosphatase 1 in Plasmodium falciparum
H Mansour, A Cabezas-Cruz, V Peucelle… - International Journal of …, 2023 - mdpi.com
The Protein Phosphatase type 1 catalytic subunit (PP1c)(PF3D7_1414400) operates in
combination with various regulatory proteins to specifically direct and control its …
combination with various regulatory proteins to specifically direct and control its …
Outcomes with first-line PD-1/PD-L1 inhibitor monotherapy for metastatic renal cell carcinoma (mRCC): a multi-institutional cohort
Introduction: The treatment landscape of metastatic renal cell carcinoma has advanced
significantly with the approval of combination regimens containing an immune checkpoint …
significantly with the approval of combination regimens containing an immune checkpoint …
Is there an overtreatment of melanoma patients at the end of their life? Results of a multicenter study on 193 melanoma patients
A Forschner, C Loquai, F Meiss… - JDDG: Journal der …, 2021 - Wiley Online Library
Background and objectives There is a lack of data regarding the situation of melanoma
patients receiving systemic therapies in their last months of life. Patients and methods All …
patients receiving systemic therapies in their last months of life. Patients and methods All …
Gibt es eine Überbehandlung von Melanompatienten am Ende ihres Lebens? Ergebnisse einer multizentrischen Studie an 193 Melanompatienten
A Forschner, C Loquai, F Meiss… - JDDG: Journal der …, 2021 - Wiley Online Library
Zusammenfassung Hintergrund und Ziele Es fehlen Daten Daten über die Situation von
Melanompatienten, die in ihren letzten Lebensmonaten systemische Therapien erhalten …
Melanompatienten, die in ihren letzten Lebensmonaten systemische Therapien erhalten …
Standard-verändernde Neuigkeiten aus der internistischen Onkologie
E Busch, L Woydack, D Jäger, S Zschäbitz - Der Klinikarzt, 2020 - thieme-connect.com
In den letzten Jahren haben Checkpoint-Inhibitoren und zielgerichtete Substanzen Einzug
gehalten in die Behandlungs-Algorithmen zahlreicher Tumorentitäten. In Kombination mit …
gehalten in die Behandlungs-Algorithmen zahlreicher Tumorentitäten. In Kombination mit …
頭頸部癌における免疫チェックポイント阻害薬と臨床での使用, および今後の展望
山﨑知子 - 日本気管食道科学会会報, 2022 - jstage.jst.go.jp
再発・遠隔転移頭頸部癌では, プラチナ不応症例に CheckMate 141 試験の結果よりニボルマブが,
ファーストラインに Keynote048 試験の結果よりペムブロリズマブが承認された 1, 2) …
ファーストラインに Keynote048 試験の結果よりペムブロリズマブが承認された 1, 2) …